表紙
市場調査レポート

髄膜炎菌性髄膜炎:パイプラインレビュー

Meningococcal Meningitis - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 253663
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
髄膜炎菌性髄膜炎:パイプラインレビュー Meningococcal Meningitis - Pipeline Review, H1 2014
出版日: 2014年04月28日 ページ情報: 英文 62 Pages
概要

髄膜炎菌性髄膜炎は、脳および脊髄を覆う膜の炎症を引き起こす感染症であり、発熱や悪寒、精神状態の変化、悪心、嘔吐、紫斑、発疹、点状出血、羞明、激しい頭痛、頚部硬直(髄膜症)などの症状があります。抗生剤の投与などの治療法があります。

当レポートでは、世界における髄膜炎菌性髄膜炎治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

髄膜炎菌性髄膜炎の概要

治療薬の開発

  • 髄膜炎菌性髄膜炎向けパイプライン製品:概要
  • 髄膜炎菌性髄膜炎向けパイプライン製品:比較分析

髄膜炎菌性髄膜炎:開発中の治療薬:企業別

髄膜炎菌性髄膜炎:開発中の治療薬:大学・研究機関別

髄膜炎菌性髄膜炎:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

髄膜炎菌性髄膜炎:開発中の製品:企業別

髄膜炎菌性髄膜炎:開発中の製品:大学・研究機関別

髄膜炎菌性髄膜炎:治療薬開発に従事している企業

  • Novartis AG
  • Pfizer Inc.
  • GlycoVaxyn AG
  • JN-International Medical Corporation
  • Beijing Tiantan Biological Products Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd

髄膜炎菌性髄膜炎:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 髄膜炎菌B群ワクチン(rDNA, コンポーネント, 沈降)
  • PF-05212366
  • 髄膜炎菌B群ワクチン(rDNA, コンポーネント, 沈降)
  • 髄膜炎菌(A,C,Y W135群)ワクチン
  • 髄膜炎菌B群ワクチン(rDNA, コンポーネント, 沈降)
  • NmVac4-ACYW135 DT
  • 髄膜炎菌(A, C, Y, W-135群)oligosaccharide diphtheria CRM197結合型ワクチン
  • 髄膜炎菌B群髄膜炎ワクチン
  • MenX莢膜多糖体ワクチン
  • 髄膜炎菌A+C群結合型ワクチン
  • 髄膜炎菌ACWY群ワクチン
  • 多糖体脳膜炎B群ワクチン
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4889IDB

Global Markets Direct's, 'Meningococcal Meningitis - Pipeline Review, H1 2014', provides an overview of the Meningococcal Meningitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meningococcal Meningitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcal Meningitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Meningococcal Meningitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Meningococcal Meningitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Meningococcal Meningitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Meningococcal Meningitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Meningococcal Meningitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Meningococcal Meningitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningococcal Meningitis Overview
  • Therapeutics Development
    • Pipeline Products for Meningococcal Meningitis - Overview
    • Pipeline Products for Meningococcal Meningitis - Comparative Analysis
  • Meningococcal Meningitis - Therapeutics under Development by Companies
  • Meningococcal Meningitis - Therapeutics under Investigation by Universities/Institutes
  • Meningococcal Meningitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Meningococcal Meningitis - Products under Development by Companies
  • Meningococcal Meningitis - Products under Investigation by Universities/Institutes
  • Meningococcal Meningitis - Companies Involved in Therapeutics Development
    • Novartis AG
    • Pfizer Inc.
    • GlycoVaxyn AG
    • JN-International Medical Corporation
    • Beijing Tiantan Biological Products Co., Ltd.
    • Beijing Minhai Biotechnology Co., Ltd
  • Meningococcal Meningitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05212366 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal (A,C,Y and W135) Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NmVac4-ACYW135 DT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal Group B Meningitis Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MenX Capsular Polysaccharide Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal A+C Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACWY Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polysaccharide Meningitis B Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Meningococcal Meningitis - Recent Pipeline Updates
  • Meningococcal Meningitis - Dormant Projects
  • Meningococcal Meningitis - Product Development Milestones
    • Featured News & Press Releases
      • Mar 20, 2014: Pfizer's Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease
      • Feb 26, 2014: Bexsero: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada
      • Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease
      • Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B
      • Dec 09, 2013: Novartis supplies MenB vaccine, Bexsero, to Princeton University to help protect students from potentially deadly outbreak
      • Nov 18, 2013: National Meningitis Association Supports the Collaborative Public Health Effort at Princeton University in Response to Outbreak
      • Aug 15, 2013: Novartis' Bexsero vaccine receives Australian approval for MenB disease
      • Jul 24, 2013: UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero vaccine
      • Jul 24, 2013: UK Panel Recommends Against Inclusion Of Novartis' Bexsero In Vaccination Programme
      • Jan 22, 2013: Novartis Receives EU Approval For First Meningitis B Vaccine Bexsero
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Meningococcal Meningitis, H1 2014
  • Number of Products under Development for Meningococcal Meningitis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Meningococcal Meningitis - Pipeline by Novartis AG, H1 2014
  • Meningococcal Meningitis - Pipeline by Pfizer Inc., H1 2014
  • Meningococcal Meningitis - Pipeline by GlycoVaxyn AG, H1 2014
  • Meningococcal Meningitis - Pipeline by JN-International Medical Corporation, H1 2014
  • Meningococcal Meningitis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014
  • Meningococcal Meningitis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Meningococcal Meningitis Therapeutics - Recent Pipeline Updates, H1 2014
  • Meningococcal Meningitis - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Meningococcal Meningitis, H1 2014
  • Number of Products under Development for Meningococcal Meningitis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Late Stage Products, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top